石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has obtained the approvals for drug production and registration for Urapidil Sustained-release Capsules (30mg) and Nicardipine Hydrochloride and Sodium Chloride Injection (200ml) from the National Medical Products Administration of China (the "NMPA"), both being under type 3 chemical drug and regarded as passing the consistency evaluation. The above two products are both the first of such approvals for the PRC entities.

Urapidil Sustained-release Capsule is mainly used for the treatment of essential hypertension, renal hypertension, hypertension caused by pheochromocytoma, and urinary dysfunction associated with benign prostatic hyperplasia. Nicardipine Hydrochloride and Sodium Chloride Injection is mainly used for emergency treatment of abnormal hypertension during surgery and for hypertensive emergencies. As stated in the Company's announcement dated 12 May 2023 and 5 March 2025, the Group's Urapidil bulk drug and Nicardipine Hydrochloride bulk drug have respectively obtained the approvals for registration from the NMPA to become bulk drugs for the preparations on the market.

The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Drotaverine Hydrochloride Injection (2ml) from the NMPA, being under type 4 chemical drug and regarded as passing the consistency evaluation. Drotaverine Hydrochloride Injection is mainly used for the treatment of smooth muscle spasms related to biliary tract diseases and smooth muscle spasms caused by urinary system diseases, and can also be used as an adjuvant therapy in smooth muscle spasms caused by gastrointestinal diseases and in the relieve of dysmenorrhea. As stated in the Company's announcement dated 6 August 2025, the Group's Drotaverine Hydrochloride bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 1 September 2025

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.